How Blackstone Life Sciences is bridging the innovation gap
Episode
20 min
Read time
2 min
Topics
Productivity, Relationships, Investing
AI-Generated Summary
Key Takeaways
- ✓Phase III Selection Discipline: Blackstone Life Sciences targets registration-enabling studies specifically because they represent the highest capital intensity but lowest clinical risk stage. Their 85% phase three success rate versus the 48% industry average stems from assembling deal teams with 14 former CEOs and 22 MD PhDs who collectively have worked on over 200 approved products, filtering a large opportunity funnel down to only the highest-conviction assets.
- ✓Three-Strategy Capital Deployment: Structure investments across three distinct models: collaboration funding for late-stage co-development with established partners like Pfizer, Sanofi, and Novartis; control-equity ownership of noncore assets spun out from large pharma; and non-dilutive royalty and debt financing for biotechs with depressed valuations. Each strategy targets a different risk-return profile and partner need, maximizing deployment flexibility across market conditions.
- ✓Non-Dilutive Financing for Biotech: When a biotech believes its market valuation has upside, royalty and debt structures preserve shareholder equity while providing substantial capital. The 2020 Alnylam deal illustrates this: Blackstone invested $2B total—$1B for 50% of Novartis Leqvio royalties plus $750M in credit and two product financings—enabling Alnylam's market cap to grow significantly without equity dilution to existing shareholders.
- ✓Spin-Out Value Creation Playbook: When acquiring noncore pharma assets, take control equity positions, secure board representation, hire experienced executives, and design the development plan from inception. The Anthos Therapeutics model—carving abelacimab from Novartis in 2019, running phase two trials showing 62–89% bleeding reduction versus Xarelto, publishing in NEJM twice, then selling back to Novartis for $3.1B—demonstrates the full cycle of this approach.
- ✓AI-Driven R&D Productivity as Near-Term Catalyst: Over the next five years, AI-powered biomarker identification, patient selection optimization, and clinical trial design will reduce late-stage attrition rates across the industry. Companies should prioritize integrating AI into target screening and commercial communication strategies now, as regulatory bodies are also exploring AI-assisted review processes that could compress approval timelines and improve capital efficiency for late-stage programs.
What It Covers
Haris Panethopoulos of Blackstone Life Sciences explains how the firm deploys over $10B AUM across three strategies—collaboration funding, asset ownership, and royalty/debt financing—to bridge the R&D funding gap at major biopharma companies, achieving an 85% phase three success rate against the industry's 48% average.
Key Questions Answered
- •Phase III Selection Discipline: Blackstone Life Sciences targets registration-enabling studies specifically because they represent the highest capital intensity but lowest clinical risk stage. Their 85% phase three success rate versus the 48% industry average stems from assembling deal teams with 14 former CEOs and 22 MD PhDs who collectively have worked on over 200 approved products, filtering a large opportunity funnel down to only the highest-conviction assets.
- •Three-Strategy Capital Deployment: Structure investments across three distinct models: collaboration funding for late-stage co-development with established partners like Pfizer, Sanofi, and Novartis; control-equity ownership of noncore assets spun out from large pharma; and non-dilutive royalty and debt financing for biotechs with depressed valuations. Each strategy targets a different risk-return profile and partner need, maximizing deployment flexibility across market conditions.
- •Non-Dilutive Financing for Biotech: When a biotech believes its market valuation has upside, royalty and debt structures preserve shareholder equity while providing substantial capital. The 2020 Alnylam deal illustrates this: Blackstone invested $2B total—$1B for 50% of Novartis Leqvio royalties plus $750M in credit and two product financings—enabling Alnylam's market cap to grow significantly without equity dilution to existing shareholders.
- •Spin-Out Value Creation Playbook: When acquiring noncore pharma assets, take control equity positions, secure board representation, hire experienced executives, and design the development plan from inception. The Anthos Therapeutics model—carving abelacimab from Novartis in 2019, running phase two trials showing 62–89% bleeding reduction versus Xarelto, publishing in NEJM twice, then selling back to Novartis for $3.1B—demonstrates the full cycle of this approach.
- •AI-Driven R&D Productivity as Near-Term Catalyst: Over the next five years, AI-powered biomarker identification, patient selection optimization, and clinical trial design will reduce late-stage attrition rates across the industry. Companies should prioritize integrating AI into target screening and commercial communication strategies now, as regulatory bodies are also exploring AI-assisted review processes that could compress approval timelines and improve capital efficiency for late-stage programs.
Notable Moment
Panethopoulos revealed that even well-capitalized large pharma companies with strong balance sheets cannot fund every pipeline asset—creating a structural, recurring funding gap that Blackstone systematically targets. This reframes the firm not as opportunistic capital, but as a permanent infrastructure layer within biopharma R&D financing.
Episode Transcript
Welcome to Fact Finders in Biopharma, a podcast series from RBC Capital Markets, where we uncover the key trends and catalysts shaping the fast moving world of biotech and pharma. I'm Rahul Sood, Managing Director in the Healthcare Investment Banking Group at RBC. Today, I'm thrilled to welcome Haris Panethopoulos, Senior Managing Director at Blackstone Life Sciences and a member of its investment committee. Harris joined Blackstone in 2018 through its acquisition of Clarus, where he served as operating partner. Over his career, he has led and shaped major companies across the biopharma ecosystem from serving as CEO and President of Ariad Pharmaceuticals to leading US and Japan operations at Mercator Serono, and helping launch and guide ventures like Anthos Therapeutics, Genovant, and Evinced. He is here to talk about how Blackstone Life Sciences is helping bridge the gap between scientific innovation and late stage development, backing numerous drug programs to date and driving high impact partnerships that are reshaping how breakthrough medicines reach patients. Paris, great to have you. Thank you for having me, Rahul. It's great to be here. Blackstone Life Sciences has carved out a unique niche, partnering with pharma biotech to fund late stage assets and oversee trials. How has your vision for Blackstone Life Sciences evolved since you came on board, and what big unmet needs are you aiming to address today? So I'm sitting here today. I'm in Cambridge, Massachusetts. Many would say that it's a center of five pharma innovation. And we have our roots in a firm called Clarus, which Blackstone acquired at the back end of 2018. Today, we have over $10,000,000,000 in AUM, and we largely focus on providing market uncorrelated returns to our investors. And we do that through funding highly innovative products at the top biopharma and medtech companies worldwide, and in turn offering patients with high unmet need the potential for better and longer lives. Phase three success rate has been eighty five percent when compared to the industry average of forty eight percent. And some examples of companies that we've collaborated with include Pfizer, Sanofi, Novartis, Merck, Takeda, Moderna, UCB, ILEM to name just a few. So under our collaboration strategy, we seek to fund registration enabling studies, which historically speaking represent the most capital intensive as well as the least risky stage of clinical development. And really the need here is that biopharma companies face significant financial challenges in developing new products due to the increase in R and D costs and funding constraints, many large pharma and medtech companies, despite typically having strong balance sheets and large budgets, can't fund all the innovation in their pipelines. So our collaboration strategy is geared to fund or co fund the late stage development of core franchise products owned by these large established companies by assuming development risk, providing our deep r and d expertise, as well as p and l relief at a time when our funded products are not generating sales for our partners. The …
Get the full transcript (2,817 words) + summary by email — free
One-time email with the complete transcript and AI summary of this episode. No account needed.
One email, no spam. We’ll also show you what SignalCast does.
You just read a 3-minute summary of a 17-minute episode.
Get Pathfinders in Biopharma summarized like this every Monday — plus up to 2 more podcasts, free.
Pick Your Podcasts — FreeKeep Reading
More from Pathfinders in Biopharma
What's driving biotech's latest rally?
Aug 31 · 23 min
Eye on AI
#337 Debdas Sen: Why AI Without ROI Will Die (Again)
Apr 23
More from Pathfinders in Biopharma
Dyne Therapeutics pioneers direct drug delivery to muscle and CNS
Jul 15 · 12 min
Invest Like the Best with Patrick O'Shaughnessy
Vlad Barbalat - Investing $120 Billion in Permanent Capital - [Invest Like the Best, EP.479]
Jun 23
Books, tools, and gear mentioned in this episode
SignalCast may earn commission on purchases via these links. As an Amazon Associate, SignalCast earns from qualifying purchases.
Products
“carving abelacimab from Novartis in 2019, running phase two trials showing 62–89% bleeding reduction versus Xarelto”
company
“The Anthos Therapeutics model—carving abelacimab from Novartis in 2019, running phase two trials showing 62–89% bleeding reduction versus Xarelto, publishing in NEJM twice, then selling back to Novartis for $3.1B”
by Blackstone
“Haris Panethopoulos of Blackstone Life Sciences explains how the firm deploys over $10B AUM across three strategies—collaboration funding, asset ownership, and royalty/debt financing—to bridge the R&D funding gap at major biopharma companies”
“collaboration funding for late-stage co-development with established partners like Pfizer, Sanofi, and Novartis”
“collaboration funding for late-stage co-development with established partners like Pfizer, Sanofi, and Novartis”
“collaboration funding for late-stage co-development with established partners like Pfizer, Sanofi, and Novartis”
“The 2020 Alnylam deal illustrates this: Blackstone invested $2B total—$1B for 50% of Novartis Leqvio royalties plus $750M in credit and two product financings”
More from Pathfinders in Biopharma
We summarize every new episode. Want them in your inbox?
What's driving biotech's latest rally?
Dyne Therapeutics pioneers direct drug delivery to muscle and CNS
4DMT targets global retina market with long-lasting genetic treatment
How it feels in the eye of an M&A bidding war
Why the MFN price battle is heading for court, not legislature
Similar Episodes
Related episodes from other podcasts
Eye on AI
Apr 23
#337 Debdas Sen: Why AI Without ROI Will Die (Again)
Invest Like the Best with Patrick O'Shaughnessy
Jun 23
Vlad Barbalat - Investing $120 Billion in Permanent Capital - [Invest Like the Best, EP.479]
The School of Greatness
Jun 1
The Neuroscience of Identity: Why You Keep Repeating the Same Patterns | Emily McDonald
10% Happier with Dan Harris
Sep 7
The Science Of Building The Life You Want | Arthur Brooks
Deep Questions with Cal Newport
Aug 31
Rethinking the Deep Life Stack (Again!) | Monday Advice
Explore Related Topics
This podcast is featured in Best Biotech Podcasts (2026) — ranked and reviewed with AI summaries.
Read this week's Investing & Markets Podcast Insights — cross-podcast analysis updated weekly.
You're clearly into Pathfinders in Biopharma.
Every Monday, we deliver AI summaries of the latest episodes from Pathfinders in Biopharma and 192+ other podcasts. Free for one show.
Start My Monday DigestNo credit card · Unsubscribe anytime